Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 14/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.36 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
| ▸ | PRKACG | P22612 | 1/20 | 0.35 |
| ▸ | PRKACB | P22694 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21531625 | 0.91 | ADORA2B (0.41) | ADORA2BADORA2AADORA1ADORA3SPR | |
| SCHEMBL20139163 | 0.86 | ADORA2B (0.37) | ADORA2BADORA2AADORA1ADORA3SPR | |
| SCHEMBL20138777 | 0.86 | CREBBP (0.43) | — | |
| SCHEMBL20138745 | 0.82 | KDM5B (0.44) | KDM5BPRMT5WDR77KDM5A | |
| SCHEMBL20143034 | 0.78 | ADORA2B (0.41) | ADORA2BADORA2AADORA1ADORA3SPR | |
| SCHEMBL20138790 | 0.75 | PDE5A (0.36) | ADORA2BADORA2AADORA1ADORA3KMT2A | |
| SCHEMBL20138922 | 0.75 | HTR7 (0.36) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL20138967 | 0.74 | PDE7A (0.36) | ADORA1 | |
| SCHEMBL20139190 | 0.72 | PDE7A (0.38) | KDM5A | |
| SCHEMBL20138964 | 0.71 | CREBBP (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-26 | — | — | US | claimed |
| US-20220079942-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-03-17 | — | — | US | claimed |
| US-11020396-B2 | Pyrimidinone derivatives as Cdc7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-01 | — | — | US | claimed |
| US-20190336502-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-11-07 | — | — | US | claimed |
| EP-3538523-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | Cancer Research Technology Limited (GB) | 2019-09-18 | — | — | EP | claimed |
| WO-2018087527-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-17 | — | — | WO | claimed |
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-26 | — | — | US | disclosed |
| CN-110088100-B | Pyrimidone derivatives as CDC7 inhibitors | 癌症研究科技有限公司 | 2023-02-17 | — | — | CN | disclosed |
| US-20220079942-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-03-17 | — | — | US | disclosed |
| US-11020396-B2 | Pyrimidinone derivatives as Cdc7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-01 | — | — | US | disclosed |
| US-20190336502-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-11-07 | — | — | US | disclosed |
| EP-3538523-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | Cancer Research Technology Limited (GB) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018087527-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190336502-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CDC7, CDK7, CDK17 | ADORA2B 4655/4885ADORA2A 4384/4885ADORA1 4090/4885 |
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CDC7, CDK7, CDK17 | ADORA2B 4655/4885ADORA2A 4384/4885ADORA1 4090/4885 |
| US-20220079942-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CDC7, CDK7, CDK17 | ADORA2B 4655/4885ADORA2A 4384/4885ADORA1 4090/4885 |
| US-11020396-B2 | Pyrimidinone derivatives as Cdc7 inhibitors | CDC7, CDK7, CDK17 | ADORA2B 4655/4885ADORA2A 4384/4885ADORA1 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.